Cirio advises Annexin Pharmaceuticals AB (publ) in connection with its rights issue

Cirio advises Annexin Pharmaceuticals AB (publ) (”Annexin”) in connection with its rights issue of shares. The rights issue is subject to subsequent approval by the Annual General Meeting, to be held on 2 May 2024.

Annexin is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company’s biological drug candidate ANXV is primarily intended for the treatment of patients with vascular injuries and inflammation, but also for cancer. The company’s share is listed on Nasdaq First North Growth Market.

Cirio advised Annexin Pharmaceuticals AB (publ) with a team headed by Maria Arnoldsson (Equity Capital Markets and Public M&A) and Per Hedman (Life sciences), together with Louise Åberg and Selma Didriksson Fröjd (Equity Capital Markets and Public M&A).